The purpose of this study was to determine whether Rifampicin was effective in slowing or
reversing the progression of multiple system atrophy (MSA). Research studies indicate that
there is an abnormality in protein synthesis and structure in parts of the brain responsible
for MSA (protein misfolding) and the drug Rifampicin could potentially prevent or reverse
this protein alteration. The study was done on participants with early MSA. The study
consisted of taking the drug 2 times a day for 12 months. Participants underwent an
evaluation of symptoms and function and will underwent a neurologic examination at the
beginning of the study, at 6 months and at 12 months. They were also be contacted at 3 and 9
months by telephone. Studies were done at 10 participating sites.
Phase:
Phase 3
Details
Lead Sponsor:
Phillip Low
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) Rare Disease Research Network Autonomic Consortium Vanderbilt University